LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics
In your lifetime, chances are someone you know will be affected by cancer.
In this episode, Stacy Blain, founder, and CSO of Concarlo Therapeutics talks about how she and a team of scientists are changing outcomes for drug-resistant patients with new classes of drugs. At Concarlo, they are developing new medications that use p27, a natural inhibitor, to stop cancer cells from multiplying in these patients, to enter the first clinical trial in 2024. For her, having an all-scientist team is valuable and has led the way and opened doors in the pharmaceutical field. She also explains why making sure everyone is seen and valued in your lab team ensures they work as a cohesive unit. Stacy encourages everyone to support science and cancer research now, not only when it hits closer to home.
Tune in to this episode to learn about new medications for drug-resistant patients and the science behind them!
Click this link to the show notes, transcript, and resources: outcomesrocket.health
